PSMA PET imaging offers several advantages, such as superior accuracy (92%) compared to conventional imaging (65%) for staging high-risk prostate cancer [54]; high sensitivity in detecting metastases, even in patients with low PSA levels [54]; and the ability to guide treatment decisions, especially in cases of biochemical recurrence [55]. This evidence concerns the gene FOLH1 and prostate cancer.